FDA tag details for this medication is offered at DailyMed. Using everolimus to treat cancer is approved for the Afinitor and Afinitor Disperz brands. Everolimus is accepted to treat transplant rejection. Everolimus is being researched in the therapy of other types of cancer. Definition from the NCI Drug Dictionary, Detailed scientific meaning and other names for this medicine. If they can aid deal with or protect against problems other than the ones they are accepted for, drugs are often studied to locate out. This patient information sheet applies only to accepted uses of the drug. Everolimus works by disrupting the growth of cancer cells, which are eventually destroyed by the body. Since the development of normal body cells might additionally be affected, other unwanted impacts will also occur. Everolimus is additionally used along with other medications to lower the body's all-natural immunity in patients that get kidney or liver transplants. When a patient gets an organ transplant, the body's leukocyte try to do away with the transplanted organ. These cells usually aid our bodies combat getting into microorganisms, but after a body organ transplant you don't want your immune system cells striking or turning down the new body organ. Viral infections may consist of active hepatitis B in people that have had liver disease B in the past. When you start therapy with among this drug, your medical care provider might inform you to start a prescription mouthwash to reduce the chance of getting mouth ulcers or sores and to lower their severity.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
|6442177||C53H83NO14||958.2||CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC||C[[email protected]@H]1CC[[email protected]]2C[[email protected]@H](/C(=C/C=C/C=C/[[email protected]](C[[email protected]](C(=O)[[email protected]@H]([[email protected]@H](/C(=C/[[email protected]](C(=O)C[[email protected]](OC(=O)[[email protected]@H]3CCCCN3C(=O)C(=O)[[email protected]@]1(O2)O)[[email protected]](C)C[[email protected]@H]4CC[[email protected]]([[email protected]@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC||InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1||HKVAMNSJSFKALM-GKUWKFKPSA-N||(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone||5.9||957.58135632||957.58135632||205||1810||0||3||14||9||68||0||15||15||0||4||4||0||1|